Evidence map›Paper›PMID 40743135›Full record

ReviewPLoS pathogens2025

Is "pre-sepsis" the new sepsis? A narrative review.

Rémy Gerard, Antoine Dewitte, Fridolin Gross, Thomas Pradeu, Maël Lemoine, Julien Goret, Maria Mamani-Matsuda

Abstract readReview
In one paragraph

Review in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Rémy GerardDepartment of Pediatrics, Neonatal Intensive Care Unit, Bordeaux University Hospital, Bordeaux, France.ORCID 0000-0002-0579-1775
Antoine DewitteUniv. Bordeaux, ImmunoConcEpT, CNRS UMR 5164, Inserm ERL 1303, Bordeaux, France.
Fridolin GrossUniv. Bordeaux, Immuno ConcEpT, CNRS UMR 5164, Bordeaux, France.
Thomas PradeuUniv. Bordeaux, Immuno ConcEpT, CNRS UMR 5164, Bordeaux, France.
Maël LemoineUniv. Bordeaux, Immuno ConcEpT, CNRS UMR 5164, Bordeaux, France.
Julien GoretUniv. Bordeaux, ImmunoConcEpT, CNRS UMR 5164, Inserm ERL 1303, Bordeaux, France.
Maria Mamani-MatsudaUniv. Bordeaux, ImmunoConcEpT, CNRS UMR 5164, Inserm ERL 1303, Bordeaux, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis is a life-threatening condition caused by a dysregulated immune response to infection, leading to organ dysfunction and high mortality. Despite advances in treatment, sepsis remains difficult to manage. Historically, the concept of sepsis evolved from ancient observations of infection-related decay to the germ theory of the 19th century. The latest Sepsis-3 definition describes sepsis as life-threatening organ dysfunction due to a dysregulated host response. However, this clinical characterization may be too late for effective intervention. The concept of endotypes and the ontological data applied to sepsis highlight the substantial heterogeneity in pathophysiological pathways leading to this endpoint. We propose a focus on the "pre-sepsis" phase, where early immune dysregulation arises before significant organ damage. This phase represents the host's initial response to infection, preceding sepsis and, thus, organ failure. Currently, there is no formal definition of "pre-sepsis", but this phase could be defined on the basis of early biological pathways in host-pathogen interactions, such as those involving endogenous carbon monoxide. By focusing on "pre-sepsis" and developing tools to detect it, clinicians could intervene earlier and potentially prevent the progression to sepsis. This approach may lead to improved outcomes and more personalized treatments, targeting specific immune pathways tailored to patient profiles. Ultimately, this shift could address existing challenges in sepsis treatment, offering new directions for clinical research and therapeutic development.

Indexed as

Host-Pathogen InteractionsMultiple Organ FailureSepsisAnimalsHumans

Identifiers

PMID40743135
PMCPMC12312982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.